- Home
- WK vs NRIX Comparison
WK vs NRIX Comparison
Compare WK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WK | NRIX |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WK | NRIX |
|---|---|---|
| Price | $52.17 | $23.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $95.30 | $30.50 |
| AVG Volume (30 Days) | 946.1K | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.53 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $884,568,000.00 | $76,987,000.00 |
| Revenue This Year | $20.85 | N/A |
| Revenue Next Year | $15.43 | $48.05 |
| P/E Ratio | $158.58 | ★ N/A |
| Revenue Growth | 19.75 | ★ 99.31 |
| 52 Week Low | $43.34 | $8.20 |
| 52 Week High | $97.10 | $25.09 |
Technical Indicators
Market Signals| Indicator | WK | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 64.37 |
| Support Level | $51.49 | $14.86 |
| Resistance Level | $52.20 | $24.88 |
| Average True Range (ATR) | 2.03 | 1.42 |
| MACD | 0.54 | 0.16 |
| Stochastic Oscillator | 78.36 | 70.76 |
Price Performance
Historical ComparisonAbout WK Workiva Inc.
Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.